Back to results
US 9,283,209 B2Granted
Oral formulations of deferasirox
AssigneeNovartis AG
InventorsIndrajit Ghosh, Jia-Ai Zhang
Life of this patent
Estimating the term…
Abstract
Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.
Claims3
A tablet for oral administration consisting of 90 mg deferasirox;
- 53.61 mg microcrystalline cellulose;
- 3.65 mg poly vinyl pyrrolidone K-30;
- 11.34 mg crospovidone;
- 0.16 mg poloxamer;
- 0.81 mg fumed silica;
- 2.43 mg magnesium stearate;
- and
- 4.86 mg seal-coat.
5 more elements
A tablet for oral administration consisting of 180 mg deferasirox;
- 107.23 mg microcrystalline cellulose;
- 7.29 mg poly vinyl pyrrolidone K-30;
- 22.68 mg crospovidone;
- 0.32 mg poloxamer;
- 1.62 mg fumed silica;
- 4.86 mg magnesium stearate;
- and
- 9.72 mg seal-coat.
5 more elements
A tablet for oral administration consisting of 360 mg deferasirox;
- 215.45 mg microcrystalline cellulose;
- 14.58 mg poly vinyl pyrrolidone K-30;
- 45.36 mg crospovidone;
- 0.65 mg poloxamer;
- 3.24 mg fumed silica;
- 9.72 mg magnesium stearate;
- and
- 19.44 mg seal-coat.
5 more elements
Dependencies are inferred from the claim text.